Freestyle Libre 2: Next-Gen CGM is Here

Where does the revolutionary system that's quickly risen from launch to the world’s leader¹ in helping people live with diabetes go from here?

To even more people in more places.

The U.S. Food and Drug Administration cleared FreeStyle Libre 2 system as an integrated CGM (iCGM), adding a pediatric designation (now for children 4 and older with diabetes) and offering more features, including optional real-time alarms to alert you when glucose levels get too high or low.²

“Diabetes growth momentum clearly continues to ramp with Libre,” wrote SVB Leerink analyst Danielle Antalffy.

The FreeStyle Libre 2 system lets users check their glucose levels as often as they like without having to fingerstick,³ a life-changing innovation that lets people live better and gain deeper understanding of their glucose levels. 

A Market Standout

The global marketplace for glucose monitoring remains vast and growing with 463 million adults living with diabetes, according to the International Diabetes Federation (IDF). This number is projected to balloon 51% to 700 million people by 2045, IDF data show.

The market for high-tech diabetes devices, which includes CGMs and insulin pumps, is approximately $7 billion, making it the fastest growing medtech market over $1 billion, according to Raymond James Financial analyst Jayson Bedford.⁴ 

FreeStyle Libre 2 is a standout in this market, here’s why:

• Unsurpassed 14-day⁵ accuracy — The FreeStyle Libre 2 system has a combined mean absolute relative difference (MARD), a measurement of performance for CGMs, of 9.3% (9.2% for adults and 9.7% for pediatrics), making it the only iCGM sensor sustaining a high level of accuracy over 14 days.
• Minute-by-minute glucose readings — FreeStyle Libre 2 system is the only iCGM system that measures glucose every minute. That’s five times more glucose readings than competitors.^1,6
  
• Longest lasting self-applied sensor — At 14 days, the next-gen FreeStyle Libre 2 system is the longest lasting iCGM sensor available.
  
• Fewer false alarms — FreeStyle Libre 2 has one third fewer false alarms for children than Dexcom’s G6.^7,8
  
• Accessible and affordable — Compared to other CGMs, FreeStyle Libre 2 will be a third of the cost in the U.S.⁹ Overall, there are more than 2 million users of FreeStyle Libre family of products worldwide,¹ and Abbott has secured partial or full reimbursement for the FreeStyle Libre portfolio in 36 countries including Canada, Japan, the United Kingdom and the U.S. 
  

Learn more about the U.S. approval of FreeStyle Libre 2.

¹Data on file. Abbott Diabetes Care.
²When alarms are turned off, notification will not be received during low or high glucose.
³Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.
⁴Raymond James Financial, Diabetes Deep-Dive: The Continued Evolution (and Acceptance) of New Diabetes Tech, February 2020.
⁵FreeStyle Libre 2 User Manual.
⁶Dexcom G6 CGM User Guide.
⁷Not based on head-to-head study.
⁸FreeStyle Libre 2 system user manual. Dexcom G6 CGM User Guide. Based on low glucose alarms set at 70 mg/dl for pediatrics.
⁹Based on a comparison of list prices of the FreeStyle Libre 14 day system versus competitors' CGM systems. FreeStyle Libre 2 system will be list priced the same rate as FreeStyle Libre 14 day system. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.